Citations

Showing 10 of 108015 citations.

Evaluation of the Intermittent Exotropia Questionnaire Using Rasch Analysis
Leske, David A. , Holmes, Jonathan M. , Melia, B. Michele, Hatt, Sarah R. , Kulp, Marjean Taylor , Scheiman, Mitchell , Herlihy, Erin P. , Miller, Aaron M. , Melia, B. Michele, Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | January 29, 2015 | Volume: 133 | Issue: 4 | Pages: 461

10.1001/jamaophthalmol.2014.5622 | PMID 25634146 Get It

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
Agathangelidis, Andreas , Hadzidimitriou, Anastasia , Sutton, Lesley-Ann, Minga, Eva, Scarfò, Lydia , Davis, Zadie , Yan, Xiao‐Jie , Plevová, Karla , Sandberg, Yorick , Vojdeman, Fie Juhl , Boudjogra, Myriam, Τζένου, Τατιάνα , Chatzouli, Maria, Chu, Charles C. , Veronese, Silvio , Gardiner, Anne, Mansouri, Larry, Smedby, Karin E. , Pedersen, Lone Bredo , Moreno, Denis, Lom, Kirsten van, Giudicelli, Véronique , Francová, Hana Skuhrová, Nguyen‐Khac, Florence , Juliusson, Gunnar , Anagnostopoulos, Αchilles , Lefranc, Marie‐Paule , Facco, Monica , Trentin, Livio , Catherwood, Mark , Montillo, Marco , Geisler, Christian H., Pospı́šilová, Šárka , Oscier, David , Jelinek, Diane F., Darzentas, Nikos , Belessi, Chrysoula, Davi, Frédéric , Ghia, Paolo , Rosenquist, Richard , Σταματόπουλος, Κώστας , Baliakas, Panagiotis , Tsanousa, Athina , Shanafelt, Tait D. , Panagiotidis, Panagiotis T. , Angelis, Lefteris , Langerak, Anton W. , Chiorazzi, Nicholas , Ghia, Paolo , Rosenquist, Richard

Mayo Clinic

Blood | January 29, 2015 | Volume: 125 | Issue: 5 | Pages: 856-859

10.1182/blood-2014-09-600874 | PMID 25634617 Get It

Key Points CLL stereotyped subset #2 (IGHV3-21/IGLV3-21) is uniformly aggressive independently of somatic hypermutation status. The prognosis for non–subset #2/IGHV3-21 CLL resembles that of the remaining CLL cases with similar somatic hypermutation status.
PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS
Dahlin, Jayme L. , Nissink, J. Willem M. , Strasser, Jessica M. , Francis, Subhashree, Higgins, LeeAnn, Zhou, Hui , Walters, Michael A. , Zhang, Zhiguo , Zhang, Zhiguo , Zhang, Zhiguo , Walters, Michael A

Mayo Clinic

Journal of Medicinal Chemistry | January 29, 2015 | Volume: 58 | Issue: 5 | Pages: 2091-2113

10.1021/jm5019093 | PMID 25634295 Get It

Neural basis of nonanalytical reasoning expertise during clinical evaluation
Durning, Steven J. , Costanzo, Michelle E. , Artino, Anthony R. , Graner, John L. , Vleuten, Cees van der , Beckman, Thomas J. , Wittich, Christopher M. , Roy, Michael J. , Holmboe, Eric S. , Schuwirth, Lambert

Mayo Clinic

Brain and Behavior | January 29, 2015 | Volume: 5 | Issue: 3 | Pages: No page available

10.1002/brb3.309 | PMID 25798328 Get It

AbstractIntroductionUnderstanding clinical reasoning is essential for patient care and medical education. Dual‐processing theory suggests that nonanalytic reasoning is an essential aspect of expertise; however, assessing nonanalytic reasoning is challenging because it is believed to occur on the subconscious level. This assumption makes concurrent verbal protocols less reliable assessment tools.MethodsFunctional magnetic resonance imaging was used to explore the neural basis of nonanalytic reasoning in internal medicine interns (novices) and board‐certified staff internists (experts) while completing United States Medical Licensing Examination and American Board of Internal Medicine multiple‐choice questions.ResultsThe results demonstrated that novices and experts share a common neural network in addition to nonoverlapping neural resources. However, experts manifested greater neural processing efficiency in regions such as the prefrontal cortex during nonanalytical reasoning.ConclusionsThese findings reveal a multinetwork system that supports the dual‐process mode of expert clinical reasoning during medical evaluation.
Angiosarcoma of the Scalp and Face
Patel, Samir H. , Hayden, Richard E. , Hinni, Michael L., Wong, William W. , Foote, Robert L. , Milani, Shadi, Halyard, Michele Y. , Ko, Stephen J. , Wu, Qing Feng

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | January 29, 2015 | Volume: 141 | Issue: 4 | Pages: 335

10.1001/jamaoto.2014.3584 | PMID 25634014 Get It

Blind men and an elephant
Kumar, Shaji

Mayo Clinic

Blood | January 29, 2015 | Volume: 125 | Issue: 5 | Pages: 745-747

10.1182/blood-2014-12-615328 | PMID 25634613 Get It

Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease
Lindor, Keith D. , Tabibian, James H.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 29, 2015 | Volume: 41 | Issue: 5 | Pages: 490-490

10.1111/apt.13068 | PMID 25631651 Get It

Minimally Disruptive Medicine: A Pragmatically Comprehensive Model for Delivering Care to Patients with Multiple Chronic Conditions
Leppin, Aaron L. , Gionfriddo, Michael R. , Montori, Víctor M.

Mayo Clinic

Healthcare | January 29, 2015 | Volume: 3 | Issue: 1 | Pages: 50-63

10.3390/healthcare3010050 | PMID 27417747 Get It

An increasing proportion of healthcare resources in the United States are directed toward an expanding group of complex and multimorbid patients. Federal stakeholders have called for new models of care to meet the needs of these patients. Minimally Disruptive Medicine (MDM) is a theory-based, patient-centered, and context-sensitive approach to care that focuses on achieving patient goals for life and health while imposing the smallest possible treatment burden on patients’ lives. The MDM Care Model is designed to be pragmatically comprehensive, meaning that it aims to address any and all factors that impact the implementation and effectiveness of care for patients with multiple chronic conditions. It comprises core activities that map to an underlying and testable theoretical framework. This encourages refinement and future study. Here, we present the conceptual rationale for and a practical approach to minimally disruptive care for patients with multiple chronic conditions. We introduce some of the specific tools and strategies that can be used to identify the right care for these patients and to put it into practice.
Reevaluation of Commercial Reagents for Detection of Histoplasma capsulatum Antigen in Urine
Theel, Elitza S. , Harring, Julie, Dababneh, Ala S. , Rollins, Leonard O., Bestrom, Jeannie E., Jespersen, Deborah J., Harring, Julie A, Bestrom, Jean E.

Mayo Clinic

Journal of Clinical Microbiology | January 29, 2015 | Volume: 53 | Issue: 4 | Pages: 1198-1203

10.1128/jcm.03175-14 | PMID 25631806 Get It

ABSTRACT Detection of the Histoplasma capsulatum urinary antigen (UAg) is among the most sensitive and rapid means to diagnose histoplasmosis. Previously, we evaluated analyte-specific reagents (ASR) manufactured by IMMY (Norman, OK) for detection of Histoplasma galactomannan (GM) in urine using an enzyme immunoassay (EIA), and we showed low positive agreement (64.5%) with the MiraVista (MVista) Histoplasma antigen (Ag) quantitative EIA (MiraVista Diagnostics, Indianapolis, IN). Here we reevaluated the IMMY GM ASR following modification of our original assay protocol and introduction of an indeterminate range. A total of 150 prospectively collected urine samples were tested with both the IMMY and MVista EIAs, and clinical histories were recorded for all study subjects. The IMMY GM ASR showed positive and negative agreements of 82.3% (14/17 samples) and 100% (121/121 samples), respectively (with exclusion of 12 indeterminate results), and overall agreement of 90% (135/150 samples) with respect to the MVista EIA. Of the three patients with negative IMMY GM ASR results and positive MVista EIA results, testing was performed for initial diagnostic purposes for one patient (<0.4 ng/ml by the MVista EIA) and UAg levels were being monitored for the remaining two patients (both <0.7 ng/ml by the MVista EIA). The MVista EIA results were positive for 6/12 samples that tested indeterminate by the IMMY GM ASR. We also show that the IMMY GM ASR can be used to serially monitor Histoplasma UAg levels. In conclusion, we demonstrate that, with modification, the IMMY GM ASR is a reliable rapid assay for detection of Histoplasma UAg.
Smoking and white matter hyperintensity progression
Sharrett, A. Richey , Jack, Clifford R. , Power, Melinda C. , Deal, Jennifer A. , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F. , Jack, Clifford R

Mayo Clinic

Neurology | January 28, 2015 | Volume: 84 | Issue: 8 | Pages: 841-848

10.1212/wnl.0000000000001283 | PMID 25632094 Get It